FindTrial
Sign In

Comparing Serum Cystatin C, Microalbuminuria, and Serum Creatinine for Early Kidney Damage Detection in People with Type 2 Diabetes

Serum Cystatin C as a biomarker for early diagnosis of kidney damage among type 2 diabetes patients as compared to microalbuminuria and serum creatinine. A cross sectional study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/06/089120
Enrollment
253
Registered
2025-06-19
Start date
Unknown
Completion date
Unknown
Last updated
2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E112- Type 2 diabetes mellitus with kidney complications

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Control Intervention1: NA: NA

Sponsors

Dr Sulakshana shridhar Baliga
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: type 2 diabetes patients aged 18 to 60 years

Exclusion criteria

Exclusion criteria: Participants with uncontrolled diabetes, uncontrolled hypertension, urolithiasis, urinary tract infections, malignancies, liver disease, thyroid gland dysfunction, Congestive heart failure, HIV, women who are pregnant will be excluded.

Design outcomes

Primary

MeasureTime frame
serum cystatin c as a biomarker for early kidney damage among type 2 diabetes patientsTimepoint: single time point(BASELINE)—

Secondary

MeasureTime frame
comparison of diagnostic accuracy with creatinine & microalbuminuriaTimepoint: single (BASELINE)—

Countries

India

Contacts

Public ContactDr Sulakshana Shridhar Baliga

Jawaharlal Nehru Medical college

drpadmajarwalvekar@jnmc.edu9448102390

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026